Form 4: Apollomics Director Tsai Hsien-Shu Executes RSU Vesting

Director Tsai Hsien-Shu acquired 500 Class A Ordinary Shares of Apollomics Inc. through the vesting of restricted stock units.

Summary

• Director Tsai Hsien-Shu acquired 500 Class A Ordinary Shares on June 15, 2026.
• The acquisition resulted from the vesting of restricted stock units (RSUs).
• Following this transaction, the director holds a total of 1,500 Class A Ordinary Shares.
• The transaction was executed at a price of $0 per share as part of a previously reported equity compensation plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Director alignment with company equity through the vesting of previously granted RSUs.

Negatives

• None identified in this filing.

Risks

• None identified in this filing.

Future Outlook

The filing notes that an additional 500 shares are scheduled to vest on September 15, 2026.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of equity compensation vesting for a corporate director, which is standard practice for publicly traded biotechnology companies.

Comparison to Industry Standards

• The vesting schedule and reporting follow standard SEC Section 16(a) compliance requirements for equity-based compensation.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard equity compensation vesting.

Next Steps

• Vesting of 500 additional shares on September 15, 2026.

Key Dates

Keywords

Apollomics, APLM, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units